Neuroprotective effect of alpha-linolenic acid against AÎ²-mediated

Subscriber access provided by UNIV OF NEW ENGLAND ARMIDALE

Bioactive Constituents, Metabolites, and Functions

Neuroprotective effect of alpha-linolenic acid against A#-mediated inflammatory responses in C6 glial cell Ah Young Lee, Myoung Hee Lee, Sanghyun Lee, and Eun Ju Cho J. Agric. Food Chem., Just Accepted Manuscript • DOI: 10.1021/acs.jafc.8b00836 • Publication Date (Web): 18 Apr 2018 Downloaded from http://pubs.acs.org on April 18, 2018

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 50

Journal of Agricultural and Food Chemistry

1

Neuroprotective effect of alpha-linolenic acid against Aβ-mediated

2

inflammatory responses in C6 glial cell

3

Ah Young Leea, Myoung Hee Leeb, Sanghyun Leec, Eun Ju Choa,*

4

a

5

University, Busan 46241, Republic of Korea.

6

b

7

Development Administration, Gyeongnam 50424, Republic of Korea.

8

c

9

of Korea.

Department of Food Science and Nutrition & Kimchi Research Institute, Pusan National

Department of Southern Area Crop Science, National Institute of Crop Science, Rural

Department of Integrative Plant Science, Chung-Ang University, Gyeonggi 17546, Republic

10 11 12 13 14 15 16 17 18 19 20

Corresponding author: Eun Ju Cho, Department of Food Science and Nutrition, Pusan

21

National University, Busan 46241, Republic of Korea. Tel: +82-51-510-2837, Fax: +82-51-

22

583-3648. E-mail address: [email protected] (E. J. Cho).

1

ACS Paragon Plus Environment


23

ABSTRACT

24

Therapeutic approaches for neurodegeneration, such as Alzheimer’s disease (AD), have been

25

widely studied. One of the critical hallmarks of AD is accumulation of amyloid beta (Aβ). Aβ

26

induces neurotoxicity and releases inflammatory mediators or cytokines through activation of

27

glial cell, and these pathological features are observed in AD patient’s brain. The purpose of

28

this study is to investigate the protective effect of alpha-linolenic acid (ALA) on Aβ25-35-

29

induced neurotoxicity in C6 glial cells. Exposure of C6 glial cells to 50 µM Aβ25-35 caused

30

cell death, over-production of nitric oxide (NO), and pro-inflammatory cytokines release

31

[interleukin (IL)-6 and tumor necrosis factor-α], while treatment of ALA increased cell

32

viability and markedly attenuated Aβ25-35-induced excessive production of NO and those

33

inflammatory cytokines. Inhibitory effect of ALA on generation of NO and cytokines was

34

mediated by down-regulation of inducible nitric oxide synthase and cyclooxygenase-2 protein

35

and mRNA expressions. In addition, ALA treatment inhibited reactive oxygen species

36

generation induced by Aβ25-35 through the enhancement of the nuclear factor-erythroid 2-

37

related factor-2 (Nrf-2) protein levels and subsequent induction of heme-oxygenase-1 (HO-1)

38

expression in C6 glial cells dose- and time-dependently. Furthermore, the levels of neprilysin

39

and insulin-degrading enzyme protein expressions, which contribute to degradation of Aβ,

40

were also increased by treatment of ALA compared to Aβ25-35–treated control group. In

41

conclusion, effects of ALA on Aβ degradation were shown to be mediated trough inhibition

42

of inflammatory responses and activation of antioxidative system, Nrf-2/HO-1 signaling

43

pathway, in C6 glial cells. Our findings suggest that ALA might have the potential for

44

therapeutics of AD.

45

KEY WORDS: alpha-linolenic acid, neuroinflammation, glial cell, amyloid beta, amyloid 2


Page 2 of 50

Page 3 of 50


46

beta degradation

3



47

INTRODUCTION

48

Alzheimer’s disease (AD) is the most common and multifactorial neurodegenerative

49

diseases. One of the pathological features of AD is the deposition of amyloid beta (Aβ), a

50

protein involved in oxidative stress, neuronal apoptosis and inflammatory responses. Many

51

previous studies have shown that the accumulation of Aβ is accompanied by high levels of

52

pro-inflammatory cytokines produced by both glial cells and neurons.1-4 Excessive

53

production of pro-inflammatory cytokines such as interleukin (IL)-1β, IL-6, and tumor

54

necrosis factor-α (TNF-α) contributes to amyloidogenic processing of the amyloid precursor

55

protein (APP). In addition, increased expression of these cytokines was found to impair Aβ

56

clearance and degradation in glial cells.5,6

57

Glial cells support and protect neurons from oxidative damage via modulation of synaptic

58

plasticity and secretion of growth factors.7-8 Several enzymatic systems have been described

59

to mediate the process of Aβ degradation in glial cells. Both neprilysin (NEP) and insulin

60

degrading enzyme (IDE) are critical Aβ-degrading enzymes that reduce Aβ accumulation in

61

AD brains.9-12 Moreover, glial cell dysfunction was shown to induce inhibition of Aβ

62

clearance, subsequent neurotoxicity, and Aβ accumulation.13 In addition, exogenous Aβ could

63

activate glial cell to generate reactive oxygen species (ROS) as well as reactive nitrogen

64

species (RNS), which promote secretion of inflammatory cytokines and inflammatory

65

process, thus contributing to AD progression.14-16 Therefore, suppression of inflammatory

66

process in glial cells has been proposed as a therapeutic strategy for neurodegenerative

67

disease.

68

A number of studies demonstrated the role of omega-3 polyunsaturated fatty acids in brain

69

development and function.17,18 However, most of these focused on neuroprotective effects of 4


Page 4 of 50

Page 5 of 50


70

eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA). Recently, plant-derived

71

omega-3 fatty acid, rather than fish-derived products containing EPA and DHA, has attracted

72

interest due to its benefits for human health.19 Alpha-linolenic acid (ALA), enriched in

73

vegetable oils such as perilla oil (containing 60-70% ALA) or linseed oil (containing 30-50%

74

ALA), has been shown to enhance neurological function including neurogenesis and synaptic

75

function in the rodent brain.20 We previously suggested that administration of perilla oil and

76

ALA improved cognitive impairment induced by Aβ25-35 in a mouse model of AD.21,22 Perilla

77

oil, which has the largest proportion of ALA, suppressed the expression of inflammatory

78

mediators, inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), in Aβ25-35-

79

injected brain tissues. Furthermore, ALA supplementation significantly enhanced the

80

expression of Aβ degrading enzyme, IDE. Other reports also supported that dietary ALA

81

modulates oxidative or inflammatory response in vitro and in vivo.23-25 However, no studies

82

have reported the neuroprotective potential of ALA in modulating glial cell function against

83

Aβ. In the present study, we assessed the anti-inflammatory properties of ALA in Aβ25-35-

84

treated C6 glial cell, and investigated the molecular mechanisms underlying regulation of

85

inflammatory response and Aβ degradation.

5



86

Page 6 of 50

MATERIALS AND METHODS

87 88

Sample preparation

89

Perilla frutescens oil was provided by Southern Area Crop Science, Rural Development

90

Administration (Miryang, Republic of Korea). ALA was obtained from perilla oil after

91

treatment with urea and cooling by high-yield methods as described in a previous study.26

92

ALA was freshly prepared as a stock solution in dimethyl sulfoxide (DMSO), and stored at

93

4˚C with nitrogen gas for stability before use. DMSO is used for dissolving hydrophobic

94

compounds including omega-3 fatty acids in vitro or cellular system.27,28 Nitrogen gas is the

95

generally used to protect oil or fatty acid from air contact, and is able to avoid the

96

contaminant. At low temperatures under nitrogen atmosphere, progression of lipid

97

peroxidation is relatively low. 29-31

98 99 100

Instruments and reagents Fetal bovine serum (FBS), Dulbecco’s modified eagle’s medium (DMEM), and

101

penicillin/streptomycin

102

dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), dichlorofluorescin diacetate

103

(DCF-DA) and DMSO were supplied by Sigma Chemical Co. (St Louis, MO, USA).

104

Radioimmunoprecipitation assay (RIPA) buffer, 30% acrylamide bis solution and pre-stained

105

protein size marker were obtained from Elpis Biotech (Daejeon, Korea). Polyvinylidene

106

fluoride (PVDF) membrane was from Millipore (Billerica, MA, USA). Primary antibodies

107

and secondary antibodies were purchased from Cell Signaling (Beverly, MA, USA).

were

supplied

by Welgene

(Daegu, Korea).

108 109

Cell culture 6


The

3-(4,5-

Page 7 of 50


110

C6 glial cells were obtained from KCLB (Korean Cell Line Bank, Seoul, Korea). The cells

111

were maintained in DMEM containing 1% penicillin/streptomycin and 10% FBS at 37°C in a

112

5% CO2 incubator with. Cells were sub-cultured with 0.05% trypsin-EDTA in phosphate

113

buffered saline (PBS).

114

115

Cell viability

116

After becoming confluent, the cells were harvested and plated at a density of 5 × 104 cells/mL

117

into 96-well palate overnight. The cells were then treated with ALA (1, 2.5, 5, and 25 µg/mL)

118

for 2 h, and followed by Aβ25-35 (50 µM) for 24 h. After incubation, cell viability was

119

determined using the MTT assay. MTT solution was added to each 96-well plate, the plate

120

was incubated for 4 h at 37°C, and the medium containing MTT was removed. The

121

incorporated formazan crystals incorporated in viable cells were solubilized with DMSO and

122

the absorbance of each well was read at 540 nm.

123

124

Measurement of nitric oxide (NO) production

125

NO production was investigated by quantifying nitrite accumulation in the medium treated

126

with Griess reagent. To measure nitrites, cell supernatants were mixed with Griess reagent at

127

1:1 volume ratio. Nitrite concentration was measured using microplate spectrophotometer at a

128

wave length of 540 nm.

129

130

Measurement of ROS production 7



131

The ROS scavenging activity of ALA was measured using DCFH-DA.32 C6 glial cells were

132

plated at a density of 5 × 104 cells/mL into 96-well plate overnight. The treatment with ALA

133

(5 and 25 µg/mL) was performed for 2 h, after which Aβ25-35 (50 µM) was added, and the

134

cells were further incubated for 24 h. The cells were then incubated with 80 µM DCFH-DA at

135

37°C for 30 min. The fluorescence was read for 60 min, at 480 nm excitation and 535 nm

136

emission, using a fluorescence plate reader (BMG LABTECH, Ortenberg, Germany).

137

138

Measurement of pro-inflammatory cytokines production

139

The supernatants of C6 glial cells treated with Aβ25-35 (50 µM) and ALA (5 and 25 µg/mL)

140

were transferred to a separate plate. The production of TNF-α and IL-6 were was measured

141

using ELISA kits (R&D system, Minneapolis, USA) according to manufacturer’s instructions.

142

143

Reverse transcription polymerase chain reaction (RT-PCR)

144

Total RNA was isolated using Trizol reagent (Invitrogen, Carlsbad, CA) according to

145

manufacturer’s instructions. Cells were lysed and transferred to microfuge tubes. RNA was

146

reverse-transcribed into cDNA and used as a template for RT-PCR amplification. The primers

147

and amplification conditions are listed in Table 1. PCR products were analyzed on 1%

148

agarose gels, and bands were visualized using LED slider imager (Maestrogen, Las Vegas,

149

NV, USA).

150 151

Western blotting 8


Page 8 of 50

Page 9 of 50


152

C6 glial cell extracts were prepared according to the manufacturer’s instructions using RIPA

153

buffer supplemented with 1× protease inhibitor cocktail. Proteins were separated by

154

electrophoresis in a precast 10-13% SDS-PAGE and blotted onto PVDF membranes. The

155

membrane was blocked with 5% skim milk solution for 1 h at room temperature, and

156

incubated overnight at 4°C with primary antibody [iNOS (1:200, Santa Cruz, CA, USA);

157

COX-2 (1:200, Santa Cruz); IL-6 (1:1000, Santa Cruz); TNF-α (1:000, Cell Signaling);

158

nuclear factor-erythroid 2-related factor-2 (Nrf-2, 1:1000, Cell Signaling, MA, USA); heme-

159

oxygenase-1 (HO-1, 1:2000, Cell Signaling); IDE (1:200, Santa Cruz, CA, USA); NEP

160

(1:1000, Millipore); and β-actin (1:200, Santa Cruz)]. The membrane was washed and

161

incubated with the appropriate HRP-conjugated secondary antibodies. Western bands were

162

visualized using a chemiluminescent imaging system (Davinci Chemi, Seoul, Korea).

163 164

Statistical analysis

165

The results are expressed as mean ± SD. Statistical significance was determined by one way

166

ANOVA followed by post-hoc analysis with Tukey’s test using IBM SPSS 23 program. The

167

significance was set at #P < 0.05,

168

from the normal group; *significantly different from the Aβ25-35-treated control group.

##

P < 0.01, *P < 0.05, **P < 0.01. #Significantly different

169 170

RESULTS

171

Effect of ALA on cell viability in Aβ25-35-treated C6 glial cells

172

The treatment with ALA at concentrations between 1 and 25 µg/mL did not show cytotoxicity

173

in C6 glial cells (data not shown). C6 glial cells were treated with ALA, and the effect on

174

Aβ25-35–induced cytotoxicity was determined. Compared to the normal group (100%), the 9



175

exposure of cells to Aβ25-35 for 24 h induced toxicity in C6 glial cells, reducing the cell

176

viability to 39.46% (Fig. 1). However, in the presence of ALA (1, 2.5, 5, and 25 µg/mL), cell

177

viability was significantly increased as compared to the cells treated with Aβ25-35 alone. These

178

results suggest that ALA protects C6 glial cell against Aβ25-35-induced cellular damage.

179

180

Effect of ALA on NO production in Aβ25-35-treated C6 glial cell

181

To investigate the effect of ALA on Aβ25-35-induced NO production in C6 glial cells, the cells

182

were treated with various concentrations of ALA (1, 2.5, 5, and 25 µg/mL), after which Aβ

183

was added for 24 h. Fig. 2 indicates significantly increased NO production by Aβ25-35

184

compared to normal group. By contrast, the treatment with ALA, especially at 25 µg/mL,

185

effectively attenuated Aβ25-35-induced NO production.

186

187

Effect of ALA on protein and mRNA expression of iNOS and COX-2 in Aβ25-35-treated C6

188

glial cells

189

To clarify the potential effects of ALA on inflammatory mediators, iNOS and COX-2, we

190

examined their protein and mRNA levels using Western blot and RT-PCR, respectively. As

191

shown in Fig. 3A, the protein levels of iNOS and COX-2 were markedly increased after Aβ25-

192

35 treatment.

193

COX-2 protein levels, as compared to control group.

194

In parallel with the inhibitory effect of ALA on iNOS and COX-2 protein over-expression, we

195

further analyzed the mRNA expression. We observed that iNOS and COX-2 mRNA levels

However, the treatment with ALA leads to a significant suppression of iNOS and

10


Page 10 of 50

Page 11 of 50


196

were also up-regulated following Aβ25-35 treatment, while the treatment with ALA leads to

197

inhibition of iNOS and COX-2 mRNA expression (Fig. 3B). These results demonstrate the

198

inhibitory effect of ALA on Aβ25-35 treatment-induced NO production associated with the

199

down-regulation of iNOS and COX-2 protein and mRNA expression in C6 glial cells.

200

201

Effect of ALA on pro-inflammatory cytokines production in Aβ25-35-treated C6 glial cells

202

Fig. 4 illustrates the effect of ALA on production of TNF-α and IL-6 pro-inflammatory

203

cytokines induced by Aβ25-35. The treatment with Aβ25-35 induced over-production of TNF-α

204

and IL-6 in C6 glial cells, as compared to non-treated group (Fig. 4A). However, ALA

205

treatment significantly decreased the over-production of both TNF-α and IL-6. In addition,

206

Aβ25-35 induced up-regulation of TNF-α and IL-6 protein expression, which was markedly

207

down-regulated by the treatment with ALA (Fig. 4B). These results demonstrate that

208

increased production of pro-inflammatory such as TNF-α and IL-6 in C6 glial cells induced

209

by Aβ25-35 was related to the inhibition of iNOS and COX-2 protein/gene expression, and that

210

ALA inhibited these inflammatory responses by regulating the expression of pro-

211

inflammatory cytokines and mediators.

212

213

Effect of ALA on ROS production in Aβ25-35-treated C6 glial cells

214

We examined whether ALA attenuates ROS production induced by Aβ25-35 in C6 glial cells.

215

Fig. 5A shows that the treatment of C6 glial cells with Aβ25-35 significantly increased ROS

216

levels in a time-dependent manner, as compared to un-treated group. Compared with Aβ25-3511



217

treated control group (100%), the treatment with ALA (5 and 25 µg/mL) significantly

218

inhibited the excess in ROS production, by decreasing it to 86.12% and 85.22%, respectively

219

(Fig. 5B).

220

221

Effect of ALA on Nrf-2/HO-1 signaling pathway in C6 glial cell

222

Given the inhibitory effect of ALA treatment on inflammatory reaction and ROS production,

223

we evaluated whether ALA regulates Nrf-2/HO-1 signaling in C6 glial cells by Western blot

224

analysis. Our results indicate that ALA promotes the up-regulation of Nrf2 protein expression,

225

and consequently, the increase in the expression of HO-1 protein a downstream target of Nrf-

226

2, in a dose- (Fig. 6A) and time-dependent manner (Fig. 6B). These results reveal that ALA-

227

dependent activation of Nrf-2/HO-1 signaling activation contributes to down-regulation of

228

neuroinflammation and ROS generation.

229

230

Effect of ALA on Aβ degradation in Aβ25-35-treated C6 glial cells

231

The effect of ALA on NEP and IDE expression in C6 glial cells was also investigated.

232

Western blot analysis showed that the treatment of cells with ALA significantly increased

233

NEP and IDE expression dose-dependently (Fig. 7). The treatment with Aβ25-35 significantly

234

reduced the levels of NEP and IDE. However, the protein levels of Aβ-degrading enzymes

235

NEP and IDE were significantly increased following the treatment with ALA. Thus our

236

results suggest that ALA may inhibit the accumulation of Aβ in the brain.

12


Page 12 of 50

Page 13 of 50

237


DISCUSSION

238

Neuroinflammation is one of the critical characteristics in the brain of AD patients.33 It has

239

been reported that the initial defense against Aβ accumulation is involved in inflammatory

240

responses including enzymatic degradation. Activated glial cells produce pro-inflammatory

241

mediators and cytokines, resulting in promote the synthesis and APP processing. Increased

242

Aβ production and deposition lead to further glial cell activation, which maintains the vicious

243

cycle.34,35 The cytokines induced by Aβ in turn reduce the expression of Aβ-degrading

244

enzymes, which drive the progression of AD.36,37 Since inflammatory responses have been

245

implicated in neuropathological changes and the development of AD, it is conceivable that

246

stimulating anti-inflammatory activity in glial cells may represent a therapeutic strategy for

247

AD.

248

Our study showed that the treatment of C6 glial cells with Aβ25-35 induced toxicity,

249

resulting into cell death. However, ALA significantly reversed the decrease in cell viability as

250

confirmed by MTT assays. Although RNS and ROS play a critical role in neurotransmission

251

and synaptic function in the brain, the over-production of those are associated with

252

neuroinflammation, which result in neurodegeneration.38 High levels of NO and pro-

253

inflammatory cytokines in activated glial cells can be considered as a pathophysiological

254

feature of AD.39 Our data revealed that Aβ25-35 elevated the levels of NO production and pro-

255

inflammatory cytokines such as TNF-α and IL-6. These findings are consistent with previous

256

studies showing activation of inflammatory mediators and cytokines expression by Aβ in

257

glial cell lines.40,41 However, ALA prominently inhibited the production of NO, TNF-α, and

258

IL-6 cytokines as well as decreased protein levels of TNF-α and IL-6 in Aβ25-35-stimulated C6

259

glial cells as shown by western blotting. It has been reported that neuroprotection against Aβ 13



260

can result from the inhibition of pro-inflammatory mediators through down-regulation of

261

iNOS or COX-2 protein.42,43 In this study, the exposure to Aβ25-35 stimuli up-regulated iNOS

262

and COX-2 protein and mRNA expression, while the ALA reduced both protein and mRNA

263

levels of iNOS and COX-2. These findings suggest that the inhibition of NO and pro-

264

inflammatory cytokines production by ALA was mediated by the effect on iNOS and COX-2

265

expression. Based on our results, we suggest that ALA attenuates Aβ25-35-induced glial

266

activation and down-regulates inflammatory neurotoxicity.

267

ROS accumulation is strongly associated with glial inflammatory responses in

268

neurodegenerative disease. Increased ROS production plays an important role in the

269

activation of iNOS and COX-2 by inflammatory stimuli such as Aβ.44 The inhibition of ROS

270

may be an effective way to protect the cells from Aβ-induced neuroinflammation. We

271

examined the intracellular ROS formation induced by Aβ25-35 in C6 glial cells. Our findings

272

reveal that ALA significantly suppresses the over-production of ROS induced by Aβ25-35. A

273

potential mechanism underlying the inhibition of pro-inflammatory cytokines was previously

274

reported that oxidative stress and inflammation were attenuated by ALA-enriched diet

275

through inactivation of nuclear factor-kappa B signaling pathway.45 Ambrozova et al. (2010)

276

also demonstrated that omega-3 fatty acids such as ALA inhibited ROS and RNS generation

277

in macrophage cells.46

278

The up-regulation of Nrf-2 and HO-1 expression is an effective strategy to resist the

279

oxidative stress. Nrf-2 has been considered as a regulator of inflammation and

280

neuroprotection.47,48 The expression of Nrf-2 can decrease Aβ-induced degeneration by

281

limiting cellular oxidative response and inflammatory damage.49 Activated Nrf-2 can induce

282

the expression of HO-1, its downstream antioxidant target. Substantial evidence also suggests 14


Page 14 of 50

Page 15 of 50


283

that up-regulation of HO-1 expression contributes to protection against cellular oxidative

284

damage and inflammation by inhibiting iNOS activity.50,51 To investigate the molecular

285

mechanism underlying the effect of ALA on inhibition of ROS generation and inflammation,

286

we examined the protein levels of Nrf-2 and HO-1 in C6 glial cells. Our data shows that the

287

treatment with ALA increased Nrf-2 activation and induced HO-1 protein expression in a

288

concentration- and time-dependent manner. Similar to our results, DHA treatment attenuated

289

neuronal injury by activating Nrf-2 and up-regulating HO-1 expression, demonstrating

290

neuroprotective effect.52 Pal and Ghosh (2012) demonstrated that ALA exerts antioxidant

291

effects by reducing lipid peroxidation and modulating antioxidant enzymes such as

292

superoxide dismutase, glutathione peroxidase and catalase.53 These results suggest that ALA

293

protects against Aβ-induced oxidative stress and neuroinflammation through induction of

294

Nrf-2/HO-1 signaling.

295

We previously showed that ALA has anti-oxidant activity as a scavenger of hydroxyl

296

radical, demonstrating that ALA is capable of inhibiting ROS production and lipid

297

peroxidation.54 Several reports have also shown that dietary omega-3 fatty acids are able to

298

modify the oxidative status by attenuating oxidative stress in vitro and in vivo.55-57

299

Polyunsaturated fatty acid (PUFA) containing two or more double bonds can react with

300

oxygen, resulting in formation of hydroperoxides. This oxidation is progressed by free radical

301

chain reaction through initiation, propagation, and termination at the bis-allylic positions.

302

However, lipids are complex, multi-component, and heterogeneous system. Miyashita (2014)

303

demonstrated that omega-3 fatty acids including ALA in micelles and liposomes can form

304

tight and unique conformation, and reduce hydroxyl compounds derived from oxidation

305

products, thus omega-3 fatty acids may protect against oxidative attack.58 In addition, the 15



306

omage-3 fatty acids can be incorporated into membrane phospholipids or bound to membrane

307

receptors, acting as inhibitor of ROS production and regulator of biological processes.59

308

Although further studies are needed to investigate the detailed physiological effects and

309

molecular mechanisms, these evidences support the antioxidant role of ALA in biological

310

system.

311

Glial-mediated oxidative stress and neuroinflammation are closely associated with the

312

degradation of Aβ in AD progression.60,61 The mechanisms underlying degradation of Aβ

313

have attracted attention given their potential therapeutic application in the treatments of AD.

314

This particularly applies to the roles of IDE and NEP, major Aβ-degrading enzymes in glial

315

cells.62-64 Since oxidative stress and neuroinflammation were attenuated in ALA-treated glial

316

cells, we investigated whether the activities of Aβ degrading enzymes are modified by the

317

treatment with ALA. In the present study, we found that treatment with Aβ25-35 resulted in a

318

significant decrease in the expression of IDE and NEP. However, ALA treatment significantly

319

increased protein expression levels of IDE and NEP, which are capable of degrading Aβ.

320

These effects of ALA on Aβ degradation may be affected by the inhibition of oxidative stress,

321

with a subsequent reduction of neuroinflammation induced by Aβ.

322

A number of studies demonstrated that omega-3 fatty acid consumption is associated with

323

lower risk of AD and slower rate of cognitive decline.65 The protective effects of omega-3

324

fatty acids, especially EPA or DHA, on AD have been well established in vitro, in vivo, and

325

by several clinical studies.66,67 EPA attenuated glial-produced pro-inflammatory cytokines,

326

thus subsequently inhibiting neuroinflammation.68 ALA deficiency induces abnormality of

327

nervous system, including neurons, astrocytes, oligodendrocytes, and endoplasmic

328

reticulum.69 Considering to protective effect of ALA on neurons, previous studies 16


Page 16 of 50

Page 17 of 50


329

demonstrated that injection or administration of ALA prevented neuronal cell death with

330

down-regulation of Bax protein expression in stroke animal models.70,71 Moreover, ALA

331

attenuated glutamate-induced neurotoxicity and promoted neuronal survival in vitro.20,72,73

332

We also confirmed that treatment of ALA reduced neuronal cell death against hydrogen

333

peroxide and Aβ by down-regulation of apoptotic signaling pathway.74,75 These results

334

suggest that ALA directly protects neuron as well as glial cells from oxidative stress. Because

335

of limited rate of conversion from ALA to EPA/DHA, the protective effect of ALA on glial

336

cells most likely does not involve bioconversion of ALA to EPA/DHA.

337

Our findings show that ALA increased cell viability and decreased ROS production in

338

Aβ25-35-treated glial cells. ALA also up-regulated the expression of Nrf-2 and HO-1,

339

demonstrated as protective against oxidative stress. The mechanisms underlying anti-

340

inflammatory effect of ALA involve interference with NO production and protein/mRNA

341

expressions of iNOS, COX-2, TNF-α, and IL-6. The induction of antioxidant activity and

342

inhibition of inflammatory cytokine release by the treatment with ALA has a potential to

343

induce degradation of Aβ as shown by promotion of IDE and NEP protein expressions. This

344

study suggests that intake of ALA should be considered as an attractive alternative to that of

345

fish oil in the treatment/prevention of neurodegenerative disorders such as AD.

346

347

ABBREVIATIONS USED

348

AD, Alzheimer’s disease; ALA, alpha-linolenic acid; APP, amyloid precursor protein; COX-2,

349

cyclooxygenase-2; DCF-DA, dichlorofluorescin diacetate; DHA, docosahexaenoic acid;

350

DMEM, Dulbecco’s modified eagle’s medium; DMSO, dimethyl sulfoxide; EPA, 17



351

eicosapentaenoic acid; FBS, fetal bovine serum; HO-1, heme-oxygenase-1; IDE, insulin

352

degrading enzyme; IL, interleukin; iNOS, inducible nitric oxide synthase; MTT, 3-(4,5-

353

dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; Nrf-2, nuclear factor-erythroid 2-

354

related factor-2; NEP, neprilysin; NO, nitric oxide; RIPA, radioimmunoprecipitation assay;

355

RNS, reactive nitrogen species; ROS, reactive oxygen species; PBS, phosphate buffered

356

saline; PUFA, polyunsaturated fatty acid; PVDF, polyvinylidene fluoride; TNF-alpha, tumor

357

necrosis factor-alpha

358

359

ACKNOWLEDGMENTS

360

This work was carried out with the support of the “Cooperative Research Program for

361

Agriculture Science & Technology Development (PJ01015603),” Rural Development

362

Administration, Republic of Korea.

18


Page 18 of 50

Page 19 of 50

363


REFERENCES

364

1. Meda, L.; Baron, P.; Prat, E.; Scarpini, E.; Scarlato, G.; Cassatella, M. A.; Rossi, F.

365

Proinflammatory profile of cytokine production by human monocytes and murin

366

microglia stimulated with Aβ(25-35). J. Neuroimmunol. 1999, 93, 45-22.

367

2. Murphy Jr, G. M.; Yang, L.; Cordell, B. Macrophage colony-stimulating factor

368

augments

369

production by microglial cells. J. Biol. Chem. 1998, 263, 20967-20971.

beta-amyloid-induced

interleukin-1,

interleukin-6,

and

nitric

oxide

370

3. Rubio-Perez, J. M.; Morllas-Ruiz, J. M. A. Review: Inflammatory process in

371

Alzheimer’s disease, role of cytokines. Scientific World Journal 2012, 2012, 756357.

372

4. Wang, W. Y.; Tan, M. S.; Yu, J. T.; Tan, L. Role of pro-inflammatory cytokines released

373

374 375

from microglia in Alzheimer’s disease. Ann. Transl. Med. 2015, 3,136. 5. Solito, E.; Sastre, M. Microglia function in Alzheimer’s disease. Front. Pharmacol. 2012, 3, 14.

376

6. Tachida, Y.; Nakagawa, K.; Saito, T.; Saido, T. C.; Honda, T.; Saito, Y.; Murayama, S.;

377

Endo, T.; Sakaguchi, G.; Kato, A.; Kitazume, S.; Hashimoto, Y. Interleukin-1 beta up-

378

regulates TACE to enhance alpha-cleavage of APP in neurons: resulting decrease in Aβ

379

production. J. Neurochem. 2008, 104, 1387-1393.

380

7. Travis, J. Glia: the brain’s other cells. Science 1994, 266, 970-972.

19



381

8. Tanaka, J.; Toku, K.; Zhang, B.; Ishihara, K.; Sakanaka, M.; Maeda, N. Astrocytes

382

prevent neuronal death induced by reactive oxygen nitrogen species. Glia 1999, 28, 85-

383

96.

384

9. Selkoe, D. J. Clearing the brain’s amyloid cobwebs. Neuron 2001, 32, 177-180.

385

10. Yosojima, K.; Akiyama, H.; McGeer, E. G.; McGeer, P. L. Reduced neprilysin in high

386

plaque areas of Alzheimer brain: a possible relationship to deficient degradation of

387

beta-amyloid peptide. Neurosci. Lett. 2001, 297, 97-100.

388 389

390

11. Lee, C. Y. D.; Landreth, G. E. The role of microglia in amyloid clearance from the AD brain. J. Neural. Transm. 2010, 117, 949-960. 12. Iwata, N.; Mizukami, H.; Shirotani, K.; Takaki, Y.; Muramatsu, S.; Lu, B.; Gerard, N. P.;

391

Gerard, C.; Ozawa, K.; Saido, T. C. Presynaptic localization of neprilysin contributes to

392

efficient clearance of amyloid-beta peptide in mouse brain. J. Neurosci. 2004, 24, 991-

393

998.

394

13. García-Alloza, M.; Ferrara, B. J.; Dodwell, S. A.; Hickey, G. A.; Hyman, B. T.; Bacskai,

395

B. J. A limited role for microglia in antibody mediated plaque clearance in APP mice.

396

Neurobiol. Dis. 2007, 28, 286-292.

397

14. Jiao, J.; Xue, B.; Zhang, L.; Gong, Y.; Li, K.; Wang, H.; Jing, L.; Xie, J.; Wang, X.

398

Triptolide inhibits amyloid-β1-42-induced TNF-α and IL-1β production in cultured rat

399

microglia. J. Neuroimmunol. 2008, 205, 32-36.

400 401

15. Lucin, K. M.; Wyss-Coray, T. Immune activation in brain aging and neurodegeneration: too much or too little? Neuron 2009, 64, 110-122. 20


Page 20 of 50

Page 21 of 50

402 403


16. Farfara, D.; Lifshitz, V.; Frenkel, D. Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer’s disease. J. Cell. Mol. Med. 2008, 12, 762-780.

404

17. McNamara, R. K.; Carison, S. E. Role of omega-3 fatty acids in brain development and

405

function: potential implications for the pathogenesis and prevention of psychopathology.

406

Prostaglandins Leukot. Essent. Fatty Acids 2006, 4-5, 329-349.

407 408

18. Dyall, S.C.; Michael-Titus, A. T. Neurological benefits of omega-3 fatty acids. Neuromolecular Med. 2008, 10, 219-235.

409

19. Crawford, M.; Galli. C.; Visioli, F.; Renaud, S.; Simopoulos, A. P.; Spector, A. A. Role

410

of plant-derived omega-3 fatty acids in human nutrition. Ann. Nutr. Metab. 2000, 44,

411

263-265.

412

20. Blondeau, N.; Nguemeni, C.; Debruyne, D. N. Subchronic alpha-linolenic acid

413

treatment enhances brain plasticity and exerts an antidepressant effect: a versatile

414

potential therapy for stroke. Neuropsychopharmacology 2009, 34, 2548-2559.

415

21. Lee, A. Y.; Choi, J. M.; Lee, J.; Lee, M. H.; Lee, S.; Cho, E. J. Effects of vegetable oils

416

with different fatty acid compositions on cognition and memory ability in Aβ25-35-

417

induced Alzheimer’s disease mouse model. J. Med. Food. 2016, 19, 912-921.

418

22. Lee, A. Y.; Lee, M. H.; Lee, S.; Cho, E. J. Alpha-linolenic acid from Perilla frutescens

419

var. japonica oil protects Aβ-induced cognitive impairment through regulation of APP

420

processing and Aβ degradation. J. Agric. Food Chem. 2017, 49, 10719-10729

421

23. Hassan, A.; Ibrahim, A.; Mbodji, K.; Coeffier, M.; Ziegler, F.; Bounoure, F.; Chardigny,

422

J. M.; Skiba, M.; Saboye, G.; Dechelotte, P.; Marion-Letellier, R. An alpha-linolenic 21



423

acid-rich formula reduces oxidative stress and inflammation by regulating NF-kappaB

424

in rats with TNBS-induced colitis. J. Nutr. 2010, 140, 1714-1721.

425

24. Chavali, S. R.; Zhong, W. W.; Forse, R. A. Dietary α-linolenic acid increases TNF-α,

426

and decreases IL-6, IL-10 in response to LPS: effects of sesamin on the ∆-5-

427

desaturation of ω6 and ω3 fatty acids in mice. Prostag. Leukotr. Ess. 1998, 58, 185-191.

428

25. Endres, S.; von Schacky, C. n-3 polyunsaturated fatty acids and human cytokine

429

synthesis. Curr. Opin. Lipidol. 1996, 7, 48-52.

430

26. Lee, J.; Lee, M. H.; Cho, E. J.; Lee, S. High-yield methods for purification of α-

431

linolenic acid from Perilla frutescens var. japonica oil. Appl. Biol. Chem. 2016, 59, 89-

432

94.

433

27. Narayanan, B. A.; Narayanan, N. K.; Simi, B.; Reddy, B. S. Modulation of inducible

434

nitric oxide synthase and related proinflammatory genes by the omega-3 fatty acid

435

docosahexaenoic acid in human colon cancer cells. Cancer Res. 2003, 63, 972-979.

436

28. Ren, J.; Han, E. J.; Chung, S. H. In vivo and in vitro anti-inflammatory activities of α-

437

linolenic acid isolated from actinidia polygama fruits. Arch. Pharm. Res. 2007, 30, 708-

438

714.

439

29. Piscopo, A.; Poiana, M. 2012. Packaging and storage of olive oil. I. Muzzalupo (Ed.),

440

Olive germplasm—the olive cultivation, Table Olive and Olive Oil Industry in Italy.

441

InTech 2012, pp. 201-222.

442 443

30. Crapiste, G. H.; Brevedan, M. I. V.; Carelli, A. A. Oxidation of sunflower oil during storage. J. Amer. Oil Chem. Soc. 1999. 76, 1437. 22


Page 22 of 50

Page 23 of 50

444 445

446 447


31. Yu, L. L.; Zhou, K. K.; Parry, J. Antioxidant properties of cold-pressed black caraway, carrot, cranberry, and hemp seed oils. Food Chem. 2005, 91, 723-729. 32. Cathcart, R.; Schwiers, E.; Ames, B. N. Detection of picomole levels of hydroperoxides using a fluorescent dichlorofluorescein assay. Anal. Biochem. 1983, 134, 111-116.

448

33. McGeer, P. L.; Itagaki, S.; Tago, H.; McGeer, E. G. Reactive microglia in patients with

449

senile dementia of the Alzheimer’s type are positive for the histocompatibility

450

glycoprotein HLA-DR. Neurosci. Lett. 1987, 79, 195-200.

451 452

453 454

34. Moore, A. H.; O’Banion, M. K. Neuroinflammation and anti-inflammatory therapy for Alzheimer’s disease. Adv. Drug Deliv. Rev. 2002, 54, 1627-1656. 35. Mrak, R. E.; Griffin, W. S. Glia and their cytokines in progression of neurodegeneration. Neurobiol. Aging 2005, 26, 349-354.

455

36. Nielsen, H. M.; Mulder, S. D.; Beliёn, J. A.; Musters, R. J.; Eikelenboom, P.; Veerhuis,

456

R. Astrocytic A beta 1-42 uptake is determined by A beta-aggregation state and the

457

presence of amyloid-associated proteins. Glia 2010, 58, 1235-1246.

458 459

37. Sastre, M.; Gentleman, S. M. NSAIDs: how they work and their prospects as therapeutics in Alzheimer’s disease. Front. Aging Neurosci. 2010, 2, 20.

460

38. Calabrese, V.; Boyd-Kimball, D.; Scapagnini, G.; Butterfield, D. A. Nitric oxide and

461

cellular stress response in brain aging and neurodegenerative disorders: the role of

462

vitagenes. In Vivo 2004, 18, 245-267.

463

39. Van Eldik, L. J.; Thompson, W. L.; Ralay Ranaivo, H.; Behanna, H. A.; Martin

464

Watterson, D. Glia proinflammatory cytokine upregulation as a therapeutic target for 23



465

neurodegenerative diseases: function-based and target-based discovery approaches. Int.

466

Rev. Neurobiol. 2007, 82, 277-296.

467

40. Jia, L.; Liu, J.; Song, Z.; Pan, X.; Chen, L.; Cui, X.; Wang, M. Berberine suppresses

468

amyloid-beta-induced inflammatory response in microglia by inhibiting nuclear factor-

469

kappaB and mitogen-activated protein kinase signaling pathways. J. Pharm. Pharmacol.

470

2012, 64, 1510-1521.

471 472

41. Cai, Z.; Hussain, M. D.; Yan, L. J. Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer’s disease. Int. J. Neurosci. 2014, 124, 307-321.

473

42. Pan, X. D.; Cen, X. C.; Zhu, Y. G.; Chen, L. M.; Zhang, J.; Haung, T. W.; Ye, Q. Y.;

474

Huang, H. P. Tripchlorolide protects neuronal cells from microglia-mediated beta-

475

amyloid neurotoxicity through inhibiting NF-kappaB and JNK signaling. Glia 2009, 57,

476

1227-1238.

477

43. Kim, H. G.; Moon, M.; Choi, J. G.; Park, G.; Kim, A. J.; Hur, J.; Lee, K. T.; Oh, M. S.

478

Donepezil inhibits the amyloid-beta oligomer-induced microglial activation in vitro and

479

in vivo. NueroToxicology 2014, 40, 23-32.

480 481

44. Boje, K. M.; Arora, P. K. Microglial-produced nitric oxide and reactive nitrogen oxides mediate neuronal cell death. Brain Res. 1992, 587, 250-256.

482

45. Ren, J.; Chung, S. H. Anti-inflammatory effect of α-linolenic acid and its mode of

483

action through the inhibition of nitric oxide production and inducible nitric oxide

484

synthase gene expression via NF-κB and mitogen-activated protein kinase pathways. J.

485

Agric. Food Chem. 2007, 55, 5073-5080. 24


Page 24 of 50

Page 25 of 50


486

46. Ambrozova, G.; Pekarova, M.; Lojek, A. Effect of polyunsaturated fatty acids on the

487

reactive oxygen and nitrogen species production by raw 264.7 macrophages. Eur. J.

488

Nutr. 2010, 49, 133.

489 490

47. Kim, J.; Cha, Y. N.; Surh, Y. J. A protective role of nuclear factor-erythroid 2-related factor-2 (Nrf2) in inflammatory disorders. Mutat. Res. 2010, 690, 12-23.

491

48. Arredondo, F.; Echeverry, C.; Abin-Carriquiry, J. A.; Blasina, F.; Antúnez, K.; Jones, D.

492

P.; Go, Y. M.; Liang, Y. L.; Dajas, F. After cellular internalization, quercetin causes Nrf2

493

nuclear translocation, increases glutathione levels, and prevents neuronal death against

494

an oxidative insult. Free Radic. Biol. Med. 2010, 49, 738-747.

495

49. Lee, C.; Park, G. H.; Lee, S. R.; Jang, J. H. Attenuation of β-amyloid-induced oxidative

496

cell death by sulforaphane via activation NF-E2-related factor 2. Oxid. Med. Cell

497

Longev. 2013, 2013, 313510.

498 499

50. Willis, D.; Moore, A. R.; Frederick, R.; Willoughby, D. A. Heme oxygenase: A novel target for the modulation of inflammatory response. Nat. Med. 1996, 2, 87-93.

500

51. Quincozes-Santos, A.; Bobermin, L. D.; Latini, A.; Wajner, M.; Souze, D. O.;

501

Gonçalves, C. A.; Gottfried, C. Resveratrol protect C6 astrocyte cell line against

502

hydrogen peroxide-induced oxidative stress through heme oxygenase 1. PLOS ONE

503

2013, 8, e64372.

504

52. Zhang, M.; Wang, S.; Mao, L.; Leak, R. K.; Shi, Y.; Zhang, W.; Hu, X.; Sun, B.; Cao,

505

G.; Gao, Y.; Xu, Y.; Chen, J.; Zhang, F. Omega-3 fatty acids protect the brain against

25



506

ischemic injury by activating Nrf2 and upregulating heme oxygenase 1. J. Neurosci.

507

2014, 34, 1903-1915.

508

53. Pal, M.; Ghosh, M. Studies on comparative efficacy of α-linolenic acid and α-

509

eleostearic acid on prevention of organic mercury-induced oxidative stress in kidney

510

and liver of rat. Food Chem. Toxicol. 2012, 50, 1066-1072.

511 512

54. Lee, A. Y.; Lee, M. H.; Lee, S.; Cho, E. J. Comparative study on antioxidant activity of vegetable oils under in vitro and cellular system. J. Agric. Sci. 2015, 7, 58-65.

513

55. Budowski, P. The omega-3 fatty acid peroxidation paradox. Redox Rep. 1996, 2, 75-77.

514

56. Shen, J.; Shen, S,; Das, U. N.; Xu, G. Effect of essential fatty acids on glucose-induced

515

cytotoxicity to retinal vascular endothelial cells. Lipids Health Dis. 2012, 11, 90.

516

57. Kim, K. B.; Nam, Y. A,; Kim, H. S.; Hayes, A. W.; Lee, B. M. α-Linolenic acid:

517

Nutraceutical, pharmacological and toxicological evaluation. Food Chem. Toxicol. 2014,

518

70, 163-178.

519 520

58. Miyashita, K. Paradox of omega-3 PUFA oxidation. Eur. J. Lipid Sci. Technol. 2014, 116, 1268-1279.

521

59. Serini, S.; Fasano, E.; Piccioni, E.; Cittadini, A. R. M.; Calviello, G. Dietary n-3

522

polyunsaturated fatty acids and the paradox of their health benefits and potential

523

harmful effects. Chem. Res. Toxicol. 2011, 24, 2093-2105.

524

60. Shinall, H.; Song, E. S.; Hersh, L. B. Susceptibility of amyloid beta peptide degrading

525

enzymes to oxidative damage: a potential Alzheimer’s disease spiral. Biochemistry

526

2005, 44, 15345-15350. 26


Page 26 of 50

Page 27 of 50

527 528


61. Mandrekar-Colucci, S.; Landreth, G. E. Microglia and inflammation in Alzheimer’s disease. CNS Neurol. Disord. Drug Targets 2010, 9, 156-167.

529

62. Farris, W.; Mansourian, S.; Chang, Y.; Lindsley, L.; Eckman, E. A.; Frosch, M. P.;

530

Eckman, C. B.; Tanzi, R. E.; Selkoe, D. J.; Guȇnette, S. XInsulin-degrading enzyme

531

regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor

532

protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U. S. A. 2010, 100, 4162-

533

4167.

534

63. Iwata, N.; Tsubuki, S.; Takaki, Y.; Shirotani, K.; Lu, B.; Gerard, N. P.; Gerard, C.;

535

Hama, E.; Lee, H. J.; Saido, Y. C. Metabolic regulation of brain Aβ by neprilysin.

536

Science. 2001, 292, 1550-1552.

537 538

539 540

64. Ries, M.; Sastre, M. Mechanisms of Aβ clearance and degradation by glial cells. Front. Aging Neurosci. 2016, 8, 160. 65. Bazinet, R. P.; Laye, S. Polyunsaturated fatty acids and their metabolites in brain function and disease. Nat. Rev. Neurosci. 2014, 15, 771-785.

541

66. Hooijmans, C. R.; Pasker-de Jong, P. C.; de Vries, R. B.; Ritskes-Hoitinga, M. The

542

effects of long-term omega-3 fatty acid supplementation on cognition and Alzheimer’s

543

pathology in animal models of Alzheimer’s disease: a systematic review and meta-

544

analysis. J. Alzheimer. Dis. 2012, 29, 191-209.

545 546

67. Cederholm, T.; Salem Jr, N.; Palmblad, J. Omega-3 fatty acids in the prevention of cognitive decline in humans. Adv. Nutr. 2013, 4, 672-676.

27



547

68. Dong, Y.; Xu, M.; Kalueff, A. B.; Song, C. Dietary eicosapentaenoic acid normalizes

548

hippocampal omega-3 and 6 polyunsaturated fatty acid profile, attenuates glial

549

activation and regulates BDNF function in a rodent model of neuroinflammation

550

induced by central interleukin-1β administration. Eur. J. Nutr. (2017 May 18. doi:

551

10.1007/s00394-017-1462-7. [Epub ahead of print]).

552

69. Bourre, J. M.; Pascal, G., Durand, G.; Masson, M.; Dumont, O.; Piciotti, M. Alterations

553

in the fatty acid composition of rat brain cells (neurons, astrocytes, and

554

oligodendrocytes) and of subcellular fraction (myelin and synaptosomes) induced by a

555

diet devoid of n-3 fatty acids. J. Neurochem.1984, 43, 342-348.

556

70. Heurteaux, C.; Laigle, C.; Blondeau, N.; Japperou, G.; Lazdunski, M. Alpha-linolenic

557

acid and riluzole treatment confer cerebral protection and improve survival after focal

558

brain ischemia. Neuroscience 2006, 137, 241-251.

559

71. Lang-lazdunski, L.; Blondeau, N.; Jarretou, G.; Lazdunski, M.; Heurteaux, C. Linolenic

560

acid prevents neuronal cell death and paraplegia after transient spinal cord ischemia in

561

rats. J. Vasc. Surg. 2003, 38, 564-575.

562 563

564 565

72. Blondeau, N.; Widmann, C.; Lazdunski, M.; Heurteaux, C. Polyunsaturated fatty acids induce ischemic and epileptic tolerance. Neuroscience 2002, 109, 231-241. 73. Lauritzen, I.; Blondeau, N.; Heurteaux, C.; Wildmann, C.; Romey, G.; Lazdunski, M. Polyunsautrated fatty acids are potent neuroprotectors. EMBO J. 2000, 19, 1784-1793.

566

74. Lee, A. Y.; Choi, J. M.; Lee, M. H.; Lee, J.; Lee, S.; Cho, E. J. Protective effects of

567

perilla oil and alpha linoleic acid on SH-SY5Y neuronal cell death induced by 28


Page 28 of 50

Page 29 of 50

568


hydrogen peroxide. Nutr. Res. Prac. 2018, 12, 93-100.

569

75. Lee, A. Y.; Lee, M. H.; Lee, S.; Cho, E. J. Alpha-linolenic acid regulates amyloid

570

precursor protein processing by mitogen-activated protein kinase pathway and neuronal

571

apoptosis in amyloid beta-induced SH-SY5Y neuronal cells. Appl. Biol. Chem. 2018,

572

61, 61-71.

29



573

FIGURE CAPTIONS

574

Figure 1. Effect of ALA on cell viability in Aβ25-35-treated C6 glial cells. Values are mean

575

± SD (n = 6).

576

ALA; Alpha-linolenic acid.

##

P < 0.01 compared to normal group; **P < 0.01 compared to control group.

577

578

Figure 2. Effect of ALA on NO production in Aβ25-35-treated C6 glial cells. Values are

579

mean ± SD (n = 6). ##P < 0.01 compared to normal group;

580

group. ALA; Alpha-linolenic acid.

**

P < 0.01 compared to control

581

582

Figure 3. Effect of the levels of ALA on iNOS and COX-2 protein (A) and mRNA (B)

583

expressions in Aβ25-35-treated C6 glial cells. ALA; Alpha-linolenic acid. Images of band are

584

from a representative experiment and bars represent the mean ± SD (n = 3). #P < 0.05, ##P

Neuroprotective effect of alpha-linolenic acid against AÎ²-mediated

Recommend Documents